Read more about the article Audit and Inspection Readiness: A Comprehensive Approach
Audit and inspection readiness - Comprehensive Approach - Lambda Therapeutic Research

Audit and Inspection Readiness: A Comprehensive Approach

At Lambda Therapeutic Research, we not only acknowledge but deeply embrace the paramount importance of inspection readiness within the clinical research industry. In an environment governed by rigorous regulations, readiness…

Continue ReadingAudit and Inspection Readiness: A Comprehensive Approach
Read more about the article Advancing Optical Coherence Tomography – OCT Imaging in Ophthalmic Studies
Advancing Optical Coherence Tomography OCT Imaging in Ophthalmic Clinical Trials

Advancing Optical Coherence Tomography – OCT Imaging in Ophthalmic Studies

Optical Coherence Tomography (OCT) is an advanced, non-invasive imaging technology that utilizes light waves to capture high-resolution, cross-sectional images of the eye's internal structures. By measuring the reflections of light,…

Continue ReadingAdvancing Optical Coherence Tomography – OCT Imaging in Ophthalmic Studies
Read more about the article Choosing the Best CRO for your Clinical Research Project: Key Factors to Consider
Choosing the Best CRO - Key Factors to Consider.

Choosing the Best CRO for your Clinical Research Project: Key Factors to Consider

Choosing the best CRO (Contract Research Organization) is pivotal for the success of your research endeavors. CROs not only provide essential services but can also serve as valuable collaborators, contributing…

Continue ReadingChoosing the Best CRO for your Clinical Research Project: Key Factors to Consider
Read more about the article Navigating Challenges in a Single-Dose Study to Evaluate Pharmacokinetic and Immunogenicity Endpoints of a Recombinant Humanized mAb
Navigating Challenges in a Single-Dose Study of a Recombinant Humanized mAb to Evaluate Pharmacokinetic and Immunogenicity Endpoints.

Navigating Challenges in a Single-Dose Study to Evaluate Pharmacokinetic and Immunogenicity Endpoints of a Recombinant Humanized mAb

Study Overview: Conducting clinical studies for monoclonal antibodies (MABs) involves meticulous planning and execution, especially for recombinant humanized mAbs administered via intravenous (i.v.) infusion. This Recombinant humanized mAb targets subdomain…

Continue ReadingNavigating Challenges in a Single-Dose Study to Evaluate Pharmacokinetic and Immunogenicity Endpoints of a Recombinant Humanized mAb
Read more about the article Clinical Research Update – Lambda Newsletter – June 2024
Clinical Research Updates - June 2024 Newsletter

Clinical Research Update – Lambda Newsletter – June 2024

Regulations, Notices & Guidance June 10, 2024: The FDA announced the "Emerging Drug Safety Technology Meetings; Program Announcement." The Center for Drug Evaluation and Research (CDER) introduced the Emerging Drug…

Continue ReadingClinical Research Update – Lambda Newsletter – June 2024
Read more about the article Overcoming Challenges in a Multicenter Psychiatry Clinical Trial: Bioequivalence Assessment of Paliperidone Palmitate Extended-Release Injectable Suspension, 546 mg
Overcoming Challenges in a Multicenter Psychiatric Clinical Trial: Bioequivalence Assessment of Paliperidone Palmitate Extended-Release Injectable Suspension, 546 mg

Overcoming Challenges in a Multicenter Psychiatry Clinical Trial: Bioequivalence Assessment of Paliperidone Palmitate Extended-Release Injectable Suspension, 546 mg

Blog

Continue ReadingOvercoming Challenges in a Multicenter Psychiatry Clinical Trial: Bioequivalence Assessment of Paliperidone Palmitate Extended-Release Injectable Suspension, 546 mg
Read more about the article Poster presented at 18th WRIB: Singlicate well assay for the analysis of Enoxaparin PD Biomarkers (Anti-Factor Xa, Anti-Factor IIa, and TFPI) for the Bioequivalence study.
WRIB Poster -Singlicate well assay for the analysis of Enoxaparin Pharmacodynamic Biomarkers (Anti-Factor Xa, Anti-Factor IIa, and TFPI) for the Bioequivalence study. - Poster presented at 18th WRIB

Poster presented at 18th WRIB: Singlicate well assay for the analysis of Enoxaparin PD Biomarkers (Anti-Factor Xa, Anti-Factor IIa, and TFPI) for the Bioequivalence study.

BLOG

Continue ReadingPoster presented at 18th WRIB: Singlicate well assay for the analysis of Enoxaparin PD Biomarkers (Anti-Factor Xa, Anti-Factor IIa, and TFPI) for the Bioequivalence study.